Skip to main content
Erschienen in: Strahlentherapie und Onkologie 6/2014

01.06.2014 | Original article

Role of brachytherapy in the treatment of cancers of the anal canal

Long-term follow-up and multivariate analysis of a large monocentric retrospective series

verfasst von: Laëtitia Lestrade, MD, Berardino De Bari, MD, Pascal Pommier, MD, PhD, Xavier Montbarbon, MD, Emilie Lavergne, Jean-Michel Ardiet, MD, Christian Carrie, MD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

There are few data on long-term clinical results and tolerance of brachytherapy in anal canal cancer. We present one of the largest retrospective analyses of anal canal cancers treated with external beam radiotherapy with/without (±) chemotherapy followed by a brachytherapy boost.

Materials and methods

We performed a retrospective analysis of clinical results in terms of efficacy and toxicity. The impact of different clinical and therapeutic variables on these outcomes was studied.

Results

From May 1992 to December 2009, 209 patients received brachytherapy after external beam radiotherapy ± chemotherapy. Of these patients, 163 were stage II or stage IIIA (UICC 2002) and 58 were N1-3. According to age, ECOG performance status (PS), and comorbidities, patients received either radiotherapy alone (58/209) or radiochemotherapy (151/209). The median follow-up was 72.8 months. The 5- and 10-year local control rates were 78.6 and 73.9 %, respectively. Globally, severe acute and late G3–4 reactions (NCI-CTC scale v. 4.0) occurred in 11.2 and 6.3 % of patients, respectively. Univariate analysis showed the statistical impact of the pelvic treatment volume (p = 0.046) and of the total dose (p = 0.02) on the risk of severe acute and late toxicities, respectively. Only six patients required permanent colostomy because of severe late anorectal toxicities.

Conclusion

After a long follow-up time, brachytherapy showed an acceptable toxicity profile and high local control rates in patients with anal canal cancer.
Literatur
1.
Zurück zum Zitat Williams M, Swampillai A, Osborne M et al Mount Vernon Colorectal Cancer Network (2013) Squamous cell carcinoma antigen: a potentially useful prognostic marker in squamous cell carcinoma of the anal canal and margin. Cancer 119:2391–2398 Williams M, Swampillai A, Osborne M et al Mount Vernon Colorectal Cancer Network (2013) Squamous cell carcinoma antigen: a potentially useful prognostic marker in squamous cell carcinoma of the anal canal and margin. Cancer 119:2391–2398
2.
Zurück zum Zitat No authors listed (1996) Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 348:1049–1054 No authors listed (1996) Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 348:1049–1054
3.
Zurück zum Zitat Bartelink H, Roelofsen F, Eschwege F et al (1997) Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European organization for research and treatment of cancer radiotherapy and gastrointestinal cooperative groups. J Clin Oncol 15:2040–2049PubMed Bartelink H, Roelofsen F, Eschwege F et al (1997) Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European organization for research and treatment of cancer radiotherapy and gastrointestinal cooperative groups. J Clin Oncol 15:2040–2049PubMed
4.
Zurück zum Zitat Flam M, John M, Pajak TF et al (1996) Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 14:2527–2539PubMed Flam M, John M, Pajak TF et al (1996) Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 14:2527–2539PubMed
5.
Zurück zum Zitat Ferrigno R, Nakamura RA, Dos Santos Novaes PE et al (2005) Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. Int J Radiat Oncol Biol Phys 61:1136–1142PubMedCrossRef Ferrigno R, Nakamura RA, Dos Santos Novaes PE et al (2005) Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. Int J Radiat Oncol Biol Phys 61:1136–1142PubMedCrossRef
6.
Zurück zum Zitat Huang K, Haas-Kogan D, Weinberg V et al (2007) Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal. World J Gastroenterol 13:895–900PubMed Huang K, Haas-Kogan D, Weinberg V et al (2007) Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal. World J Gastroenterol 13:895–900PubMed
8.
Zurück zum Zitat Gerbaulet A, Pötter R, Mazeron JJ et al (2002) The GEC ESTRO Handbook of Brachytherapy (ISBN 90–804532–6). Bruxelles, pp. 505–514. (The Authors and ESTRO) Gerbaulet A, Pötter R, Mazeron JJ et al (2002) The GEC ESTRO Handbook of Brachytherapy (ISBN 90–804532–6). Bruxelles, pp. 505–514. (The Authors and ESTRO)
9.
Zurück zum Zitat Papillon J, Montbarbon JF, Gerard JP et al (1989) Interstitial curietherapy in the conservative treatment of anal and rectal cancers. Int J Radiat Oncol Biol Phys 17:1161–1169PubMedCrossRef Papillon J, Montbarbon JF, Gerard JP et al (1989) Interstitial curietherapy in the conservative treatment of anal and rectal cancers. Int J Radiat Oncol Biol Phys 17:1161–1169PubMedCrossRef
10.
Zurück zum Zitat Chapet O, Gerard JP, Riche B et al (2005) Prognostic value of tumor regression evaluated after first course of radiotherapy for anal canal cancer. Int J Radiat Oncol Biol Phys 63:1316–1324PubMedCrossRef Chapet O, Gerard JP, Riche B et al (2005) Prognostic value of tumor regression evaluated after first course of radiotherapy for anal canal cancer. Int J Radiat Oncol Biol Phys 63:1316–1324PubMedCrossRef
11.
Zurück zum Zitat Tournier-Rangeard L, Peiffert D, Lafond C et al (2007) Long-term results and prognostic factors of squamous cell carcinoma of the anal canal treated by irradiation. Cancer Radiother 11:169–177PubMedCrossRef Tournier-Rangeard L, Peiffert D, Lafond C et al (2007) Long-term results and prognostic factors of squamous cell carcinoma of the anal canal treated by irradiation. Cancer Radiother 11:169–177PubMedCrossRef
12.
Zurück zum Zitat Sobin LH, Gospodarowicz MK, Wittekind Ch (Eds) (2009) TNM classification of malignant tumors, 7th edn. Wiley-Blackwell, Oxford . (ISBN 978–1–4443–3241–4) Sobin LH, Gospodarowicz MK, Wittekind Ch (Eds) (2009) TNM classification of malignant tumors, 7th edn. Wiley-Blackwell, Oxford . (ISBN 978–1–4443–3241–4)
14.
Zurück zum Zitat Womack NR, Morrison JF, Williams NS (1988) Prospective study of the effects of postanal repair in neurogenic faecal incontinence. Br J Surg 75:48–52PubMedCrossRef Womack NR, Morrison JF, Williams NS (1988) Prospective study of the effects of postanal repair in neurogenic faecal incontinence. Br J Surg 75:48–52PubMedCrossRef
15.
Zurück zum Zitat De Bari B, Bosset JF, Gérard JP et al (2012) Evidences in multidisciplinary management of rectal cancer. Cancer Radiother 16:711–720PubMedCrossRef De Bari B, Bosset JF, Gérard JP et al (2012) Evidences in multidisciplinary management of rectal cancer. Cancer Radiother 16:711–720PubMedCrossRef
16.
Zurück zum Zitat Aggarwal A, Gayadeen S, Robinson D et al (2012) Clinical target volumes in anal cancer: calculating what dose was likely to have been delivered in the UK ACT II trial protocol. Radiother Oncol 103:341–346 Aggarwal A, Gayadeen S, Robinson D et al (2012) Clinical target volumes in anal cancer: calculating what dose was likely to have been delivered in the UK ACT II trial protocol. Radiother Oncol 103:341–346
17.
Zurück zum Zitat Nieder C (2013) Concurrent radiochemotherapy with 5-FU/mitomycin remains standard treatment for anal carcinoma. Long-term results of the phase III RTOG 98–11 trial. Strahlenther Onkol 189:512–513PubMedCrossRef Nieder C (2013) Concurrent radiochemotherapy with 5-FU/mitomycin remains standard treatment for anal carcinoma. Long-term results of the phase III RTOG 98–11 trial. Strahlenther Onkol 189:512–513PubMedCrossRef
18.
Zurück zum Zitat Zilli T, Schick U, Ozsahin M et al (2012) Node-negative T1-T2 anal cancer: radiotherapy alone or concomitant chemoradiotherapy? Radiother Oncol 102:62–67 Zilli T, Schick U, Ozsahin M et al (2012) Node-negative T1-T2 anal cancer: radiotherapy alone or concomitant chemoradiotherapy? Radiother Oncol 102:62–67
19.
Zurück zum Zitat Lestrade L, De Bari B, Montbarbon X et al (2013) Radiochemotherapy and brachytherapy could be the standard treatment of anal canal cancer in elderly patients? A retrospective single centre analysis. Med Oncol 30:402PubMedCrossRef Lestrade L, De Bari B, Montbarbon X et al (2013) Radiochemotherapy and brachytherapy could be the standard treatment of anal canal cancer in elderly patients? A retrospective single centre analysis. Med Oncol 30:402PubMedCrossRef
20.
Zurück zum Zitat De Bari B, Lestrade L, Chekrine T et al (2012) Should the treatment of anal carcinoma be adapted in the elderly? A retrospective analysis of acute toxicities in a French centre and a review of the literature (in French). Cancer Radiother 16:52–57 De Bari B, Lestrade L, Chekrine T et al (2012) Should the treatment of anal carcinoma be adapted in the elderly? A retrospective analysis of acute toxicities in a French centre and a review of the literature (in French). Cancer Radiother 16:52–57
21.
Zurück zum Zitat Fraunholz I, Rabeneck D, Gerstein J et al (2011) Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for anal carcinoma: are there differences between HIV-positive and HIV-negative patients in the era of highly active antiretroviral therapy? Radiother Oncol 98:99–104 Fraunholz I, Rabeneck D, Gerstein J et al (2011) Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for anal carcinoma: are there differences between HIV-positive and HIV-negative patients in the era of highly active antiretroviral therapy? Radiother Oncol 98:99–104
22.
Zurück zum Zitat Fraass BA, Moran JM (2012) Quality, technology and outcomes: evolution and evaluation of new treatments and/or new technology. Semin Radiat Oncol 22:3–10. (Review) Fraass BA, Moran JM (2012) Quality, technology and outcomes: evolution and evaluation of new treatments and/or new technology. Semin Radiat Oncol 22:3–10. (Review)
23.
Zurück zum Zitat Valentini V, Bourhis J, Hollywood D (2012) ESTRO 2012 strategy meeting: vision for radiation oncology. Radiother Oncol 103:99–102 Valentini V, Bourhis J, Hollywood D (2012) ESTRO 2012 strategy meeting: vision for radiation oncology. Radiother Oncol 103:99–102
24.
Zurück zum Zitat Reddy S, Lee MS, Bonomi P et al (1994) Radiation therapy in the conservative treatment of carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 29:17–23CrossRef Reddy S, Lee MS, Bonomi P et al (1994) Radiation therapy in the conservative treatment of carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 29:17–23CrossRef
25.
Zurück zum Zitat Peiffert D, Bey P, Pernot M et al (1997) Conservative treatment by irradiation of epidermoid cancers of the anal canal: prognostic factors of tumoral control and complications. Int J Radiat Oncol Biol Phys 37:313–324PubMedCrossRef Peiffert D, Bey P, Pernot M et al (1997) Conservative treatment by irradiation of epidermoid cancers of the anal canal: prognostic factors of tumoral control and complications. Int J Radiat Oncol Biol Phys 37:313–324PubMedCrossRef
26.
Zurück zum Zitat Weber DC, Kurtz JM, Allal AS (2001) The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy. Int J Radiat Oncol Biol Phys 50:675–680PubMedCrossRef Weber DC, Kurtz JM, Allal AS (2001) The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy. Int J Radiat Oncol Biol Phys 50:675–680PubMedCrossRef
27.
Zurück zum Zitat Engineer R, Mallik S, Mahantshetty U et al (2010) Impact of radiation dose on locoregional control and survival on squamous cell carcinoma of anal canal. Radiother Oncol 95:283–287PubMedCrossRef Engineer R, Mallik S, Mahantshetty U et al (2010) Impact of radiation dose on locoregional control and survival on squamous cell carcinoma of anal canal. Radiother Oncol 95:283–287PubMedCrossRef
28.
Zurück zum Zitat Widder J, Kastenberger R, Fercher E et al (2008) Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients. Radiother Oncol 87:367–375 Widder J, Kastenberger R, Fercher E et al (2008) Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients. Radiother Oncol 87:367–375
29.
Zurück zum Zitat Touboul E, Schlienger M, Buffat L et al (1994) Epidermoid carcinoma of the anal canal. Results of curative-intent radiation therapy in a series of 270 patients. Cancer 73:1569–1579PubMedCrossRef Touboul E, Schlienger M, Buffat L et al (1994) Epidermoid carcinoma of the anal canal. Results of curative-intent radiation therapy in a series of 270 patients. Cancer 73:1569–1579PubMedCrossRef
30.
Zurück zum Zitat Dewas CV, Maingon P, Dalban C et al (2012) Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer? Radiat Oncol 7:201PubMedCentralPubMedCrossRef Dewas CV, Maingon P, Dalban C et al (2012) Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer? Radiat Oncol 7:201PubMedCentralPubMedCrossRef
31.
Zurück zum Zitat Brooks CJ, Lee YK, Aitken K et al (2013) Organ-sparing intensity-modulated radiotherapy for anal cancer using the actii schedule: a comparison of conventional and intensity-modulated radiotherapy plans. Clin Oncol (R Coll Radiol) 25:155–61CrossRef Brooks CJ, Lee YK, Aitken K et al (2013) Organ-sparing intensity-modulated radiotherapy for anal cancer using the actii schedule: a comparison of conventional and intensity-modulated radiotherapy plans. Clin Oncol (R Coll Radiol) 25:155–61CrossRef
32.
Zurück zum Zitat Saarilahti K, Arponen P, Vaalavirta L et al (2008) The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer. Radiother Oncol 87:383–390PubMedCrossRef Saarilahti K, Arponen P, Vaalavirta L et al (2008) The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer. Radiother Oncol 87:383–390PubMedCrossRef
Metadaten
Titel
Role of brachytherapy in the treatment of cancers of the anal canal
Long-term follow-up and multivariate analysis of a large monocentric retrospective series
verfasst von
Laëtitia Lestrade, MD
Berardino De Bari, MD
Pascal Pommier, MD, PhD
Xavier Montbarbon, MD
Emilie Lavergne
Jean-Michel Ardiet, MD
Christian Carrie, MD
Publikationsdatum
01.06.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 6/2014
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-014-0628-y

Weitere Artikel der Ausgabe 6/2014

Strahlentherapie und Onkologie 6/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.